DoW Traumatic Brain Injury and Psychological Health, Clinical Trial Award

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including health care products, technologies and/or practice guidelines. Distinctive Features: Funding from this award mechanism must support a clinical trial.· Clinical trials may be designed to evaluate a wide range of interventions, including new drugs, biologics, medical devices, diagnostics, therapies and behavioral health strategies.· Preliminary data are required.· The inclusion of community-based participatory research (CBPR) approaches is required.· The CTA offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research.○ Research Level 1: Supports proof-of-principle pilot studies, as well as phase 1 and phase 2 clinical trials.○ Research Level 2: Supports larger-scale and advanced clinical trials that evaluate effectiveness in relevant patient populations.· Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.

Estimated total programme funding: USD 18600000

Expected number of awards: 6

CFDA number(s): 12.420

Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.